↑Ruben SM, Klement JF, Coleman TA, Maher M, Chen CH, Rosen CA (Jun 1992). "I-Rel: a novel rel-related protein that inhibits NF-kappa B transcriptional activity". Genes Dev. 6 (5): 745–60. doi:10.1101/gad.6.5.745. PMID1577270.
↑Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT (March 2004). "The c-Rel transcription factor and B-cell proliferation: a deal with the devil". Oncogene. 23 (13): 2275–86. doi:10.1038/sj.onc.1207410. PMID14755244.
Further reading
Rayet B, Gélinas C (2000). "Aberrant rel/nfkb genes and activity in human cancer". Oncogene. 18 (49): 6938–47. doi:10.1038/sj.onc.1203221. PMID10602468.
Neumann M, Tsapos K, Scheppler JA, et al. (1992). "Identification of complex formation between two intracellular tyrosine kinase substrates: human c-Rel and the p105 precursor of p50 NF-kappa B.". Oncogene. 7 (11): 2095–104. PMID1437141.
Kochel T, Rice NR (1992). "v-rel- and c-rel-protein complexes bind to the NF-kappa B site in vitro". Oncogene. 7 (3): 567–72. PMID1549370.
Davis N, Ghosh S, Simmons DL, et al. (1991). "Rel-associated pp40: an inhibitor of the rel family of transcription factors". Science. 253 (5025): 1268–71. doi:10.1126/science.1891714. PMID1891714.
Lim MY, Davis N, Zhang JY, Bose HR (1990). "The v-rel oncogene product is complexed with cellular proteins including its proto-oncogene product and heat shock protein 70". Virology. 175 (1): 149–60. doi:10.1016/0042-6822(90)90195-W. PMID2155506.
Brownell E, Mittereder N, Rice NR (1989). "A human rel proto-oncogene cDNA containing an Alu fragment as a potential coding exon". Oncogene. 4 (7): 935–42. PMID2666912.
Xu X, Gélinas C (1995). "The v-Rel oncoprotein complexes with new Rel- and RelA-related proteins in transformed cells". Virology. 207 (2): 362–8. doi:10.1006/viro.1995.1095. PMID7886940.
Mackman N (1994). "Protease inhibitors block lipopolysaccharide induction of tissue factor gene expression in human monocytic cells by preventing activation of c-Rel/p65 heterodimers". J. Biol. Chem. 269 (42): 26363–7. PMID7929355.